JPMorgan Chase Financial Company LLC, a subsidiary of JPMorgan Chase & Co., has announced the issuance of Auto Callable Accelerated Barrier Notes linked to the Russell 2000 Index, with a maturity date of October 5, 2027. The notes, designed for investors seeking an early exit at a premium if the Index reaches or exceeds the Call Value on the Review Date of October 6, 2025, offer a minimum Call Premium Amount of $100.00 per $1,000 principal amount note. The notes also cater to investors looking for an uncapped return of twice any appreciation of the Index at maturity, provided the notes have not been automatically called. The notes are unsecured and unsubordinated obligations of JPMorgan Financial, with JPMorgan Chase & Co. providing a full and unconditional guarantee. The pricing...Show More

JPMorgan Chase Financial Company LLC, a subsidiary of JPMorgan Chase & Co., has announced the issuance of Auto Callable Accelerated Barrier Notes linked to the Russell 2000 Index, with a maturity date of October 5, 2027. The notes, designed for investors seeking an early exit at a premium if the Index reaches or exceeds the Call Value on the Review Date of October 6, 2025, offer a minimum Call Premium Amount of $100.00 per $1,000 principal amount note. The notes also cater to investors looking for an uncapped return of twice any appreciation of the Index at maturity, provided the notes have not been automatically called. The notes are unsecured and unsubordinated obligations of JPMorgan Financial, with JPMorgan Chase & Co. providing a full and unconditional guarantee. The pricing date is set for on or about September 30, 2024, with the settlement date expected to be on or about October 3, 2024. The notes are subject to market disruption events and other postponements as detailed in the product supplement. The notes do not pay interest and investors must be willing to forgo dividend payments and potentially lose some or all of their principal at maturity. The offering is part of a broader structured investment strategy by JPMorgan and involves risks detailed in the accompanying prospectus supplement and product supplement.